Mumbai, February 4, 2022: Bayer CropScience Limited (BSE: 506285) announced today its unaudited results for the quarter and nine months ended December 31, 2021.

In the third quarter (Q3) of Financial Year (FY) 2021-22, Bayer CropScience Limited (BCSL) earned Revenue from Operations of ₹ 9,901 million, as compared to ₹ 9,182 million in the corresponding period of FY 2020-21. Profit Before Exceptional Items and Tax stood at ₹ 593 million, compared to ₹ 1,061 million in the corresponding period of FY 2020-21. Profit Before Tax (After Exceptional Items) stood at ₹ 1,178 million as compared to ₹ 1,061 million in the corresponding period of FY 2020-21.

For the nine months ended December 31, 2021, BCSL reported Revenue from Operations of ₹ 37,711 million, compared to ₹ 35,276 million for the corresponding period in FY 2020-21. Profit Before Exceptional Items and Tax for the nine months ended December 31, 2021 stood at ₹ 5,988 million, compared to ₹ 7,159 million for the corresponding period in FY 2020-21. Profit Before Tax (After Exceptional Items) stood at ₹ 6,573 million as compared to ₹ 7,147 million in the corresponding period of FY 2020-21.

Commenting on the company’s performance, Simon-Thorsten Wiebusch, Executive Director, Bayer CropScience Ltd. said, “Our Q3 revenue from operations has registered an 8% growth over the same period last year despite unseasonal rains, crop infestations and a challenging rabi corn season. Growth was largely driven by our Crop Protection portfolio that witnessed a surge in demand with double-digit liquidation growth sustained by our strategy of prudent channel management and demand generation. Overall profitability was impacted by higher input and operational costs which included building out new business models for increasing market reach to smallholders, corn seed returns and obsolescence effects, offset by the exceptional income arising from the sale of the business of mustard, cotton, millet and sorghum seeds.”

He further stated, “Enhancing real-time agronomy advisory, farm collectivization efforts and driving market linkages through Farmer Producer Organizations (FPOs) and digitalization are important drivers to transform Indian agriculture. Bayer stands committed to maximize its efforts to benefit smallholder farmers, expand the base of its Better Life Farming centers, create gender smart interventions, double down on its sustainability efforts and make Indian agriculture competitive.”

During April to December 2021, Bayer conducted drone trials for spraying purposes as an agriculture industry-first. Bayer’s Better Life Farming (BLF) global value chain initiative also entered into multiple strategic alliances to support over 500,000 smallholder farmers across the country.

About Bayer 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, please visit www.bayer.com. 

Media Contact 

Snigdha Vishal

Communications, Bayer CropScience Limited

Email:Snigdha.Vishal@bayer.com 

Forward-Looking Statements 

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com.The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.